Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Mersana Therapeutics Inc (MRSN)

Mersana Therapeutics Inc (MRSN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 709,726
  • Shares Outstanding, K 71,762
  • Annual Sales, $ 830 K
  • Annual Income, $ -88,050 K
  • 60-Month Beta 2.46
  • Price/Sales 841.56
  • Price/Cash Flow N/A
  • Price/Book 5.00
Trade MRSN with:

Options Overview

Details
  • Implied Volatility 91.15%
  • Historical Volatility 195.50%
  • IV Percentile 67%
  • IV Rank 54.47%
  • IV High 126.52% on 12/15/20
  • IV Low 48.82% on 07/02/21
  • Put/Call Vol Ratio 0.33
  • Today's Volume 463
  • Volume Avg (30-Day) 506
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 1,043
  • Open Int (30-Day) 908

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.58
  • Number of Estimates 5
  • High Estimate -0.56
  • Low Estimate -0.59
  • Prior Year -0.33
  • Growth Rate Est. (year over year) -75.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.46 +16.90%
on 09/10/21
14.80 -33.18%
on 09/09/21
-1.85 (-15.76%)
since 08/17/21
3-Month
8.46 +16.90%
on 09/10/21
14.80 -33.18%
on 09/09/21
-4.46 (-31.08%)
since 06/17/21
52-Week
8.46 +16.90%
on 09/10/21
29.09 -66.00%
on 12/29/20
-14.34 (-59.18%)
since 09/17/20

Most Recent Stories

More News
New Strong Sell Stocks for September 14th

ATR, FTAI, HGEN, LMB, and MRSN have been added to the Zacks Rank #5 (Strong Sell) List on September 14, 2021.

ATR : 121.23 (-0.87%)
FTAI : 25.14 (-0.36%)
LMB : 6.46 (-5.83%)
HGEN : 6.83 (+2.55%)
MRSN : 9.89 (+1.85%)
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high...

MRSN : 9.89 (+1.85%)
Mersana Therapeutics Announces Appointment of Tushar Misra, Ph.D., as Chief Manufacturing Officer

Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high...

MRSN : 9.89 (+1.85%)
Mersana Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business Update

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high...

MRSN : 9.89 (+1.85%)
Mersana Therapeutics to Present at the 12th Annual Wedbush PacGrow Healthcare Conference

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high...

MRSN : 9.89 (+1.85%)
Mersana Therapeutics to Host Conference Call Announcing Second Quarter 2021 Financial Results and Business Updates

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high...

MRSN : 9.89 (+1.85%)
Mersana Therapeutics Announces Initiation of the UPGRADE Phase 1 Platinum Combination Cohort for UpRi in Platinum-Sensitive Ovarian Cancer

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high...

MRSN : 9.89 (+1.85%)
New Strong Sell Stocks for May 28th

ACET, FURY, KRYS, MRSN, and NBEV have been added to the Zacks Rank #5 (Strong Sell) List on May 28, 2021

ACET : 7.19 (+2.13%)
NBEV : 1.3900 (-2.80%)
KRYS : 59.19 (+4.78%)
MRSN : 9.89 (+1.85%)
FURY : 0.6900 (+0.55%)
Mersana Therapeutics to Present at Jefferies Virtual Healthcare Conference

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high...

MRSN : 9.89 (+1.85%)
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -28.21% and -95.60%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?...

MRSN : 9.89 (+1.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Mersana Therapeutics, Inc. is a biotechnology company. It focused on discovering and developing a pipeline of antibody drug conjugates. The company's product candidates include XMT-1522 and XMT-1536 which are in clinical stage. Mersana Therapeutics, Inc. is based in CAMBRIDGE, United States.

See More

Key Turning Points

3rd Resistance Point 10.46
2nd Resistance Point 10.22
1st Resistance Point 10.06
Last Price 9.89
1st Support Level 9.65
2nd Support Level 9.41
3rd Support Level 9.25

See More

52-Week High 29.09
Fibonacci 61.8% 21.21
Fibonacci 50% 18.77
Fibonacci 38.2% 16.34
Last Price 9.89
52-Week Low 8.46

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar